Hyperimmunized Egg Antibodies for Enterococcus-Driven Liver Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcoholic liver disease (ALD) and graft-versus-host disease (GVHD) are inadequate, with corticosteroids providing only marginal effectiveness and early liver transplantation being limited, while the role of Enterococcus faecalis and its cytolysin toxin in exacerbating these conditions is not fully addressed.
Innovation Solution
Administration of a hyperimmunized egg product from an egg-producing animal, enriched with antibodies to Enterococcus faecalis and Enterococcus faecalis cytolysin toxin, to provide therapeutic benefits in treating or preventing ALD and GVHD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat alcoholic liver disease, then some therapeutic effect is achieved, but the effectiveness is only marginal
Solution Approach 1:
The patent extracts and targets the specific pathogenic factor (Enterococcus faecalis and its cytolysin toxin) that exacerbates alcoholic liver disease, rather than using broad-spectrum corticosteroids. This is achieved through hyperimmunized egg products containing antibodies specifically directed against E. faecalis and cytolysin, providing targeted therapy that addresses the root cause rather than just suppressing symptoms
Solution Approach 2:
The patent employs preliminary immunization of egg-producing animals with E. faecalis and cytolysin antigens before collecting eggs. This preliminary action creates hyperimmunized eggs containing high levels of specific antibodies, which are then administered to patients to prevent or treat ALD before severe damage occurs
2Reliability
If early liver transplantation is performed, then curative therapy is provided, but it is limited to select centers and a limited group of patients
Solution Approach 1:
The patent develops a universal therapeutic approach using hyperimmunized egg products that can be administered to any patient with alcoholic liver disease regardless of location or eligibility criteria. The egg-based delivery system is versatile and can be produced and distributed widely, making curative therapy accessible beyond select transplantation centers
Solution Approach 2:
The patent uses eggs as a disposable, cost-effective delivery vehicle for antibodies. Rather than expensive transplantation procedures, the treatment utilizes readily available egg products that can be produced at scale, making curative therapy economically accessible to a broader patient population
3Object-affected harmful factors
If hyperimmunized egg product is administered, then liver injury and Enterococcus faecalis levels are reduced, but the mechanism of action involves complex immune responses
Solution Approach 1:
The patent uses hyperimmunized egg products as an intermediary delivery system that contains pre-formed antibodies against E. faecalis and cytolysin. These antibodies act as mediators that directly neutralize the harmful bacteria and toxin in the patient's system, simplifying the therapeutic mechanism compared to inducing an immune response from scratch
Solution Approach 2:
The patent creates a copy of the protective immune response by producing antibodies in egg-producing animals through hyperimmunization. These copied antibodies are then delivered to patients via hyperimmunized egg products, providing the same protective effect without requiring the patient's own immune system to mount a response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hyperimmunized egg product effectively reduces liver injury and Enterococcus faecalis levels, offering a promising treatment for ALD and mitigating GVHD, with potential for oral or intravenous administration.
Implementation Method 1
administration of a hyperimmunized egg product from an egg-producing animal, enriched with antibodies to Enterococcus faecalis and Enterococcus faecalis cytolysin toxin
Data Source
AI summary
In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.